Neurocrine Biosciences has initiated a Phase I clinical study to evaluate NBIP-'1968 as a potential treatment for obesity.

The post Neurocrine begins Phase I trial of NBIP-‘1968 triple agonist for obesity appeared first on Clinical Trials Arena.